Healthcare & Pharmaceuticals

Last week, after its findings revealed that the combination of hormones taken by some 6 million women was doing more harm than good, causing an increase in heart attacks, breast cancer, blood clots, and strokes, a national study was halted mid-stream. Wyeth, which has raked in more than $2 billion a year from its top-selling hormone therapies is now watching its stock price dive.
Why don't drug companies invest enough money in treating malaria and tuberculosis? A recent study published in the Lancet magazine estimates that 1,238,000 people died from malaria in 2010. Surely a wonder drug that stops these diseases would be wildly profitable?
U.S. corporations gave away $18.15 billion in charitable donations in 2012 - a combination of cash, grants, and in-kind goods - up 12.2 percent in nominal terms over the previous year. A closer look reveals profit motives, notably for pharmaceutical companies and retail chain Wal-Mart.
On the opening day of the RNC, ACT UP members dropped a giant 30 by 75 foot banner from a highly visible location. The activists demand that George W. Bush take a stand against high drug prices that result in the deaths of millions of people with HIV in Africa and worldwide.
The World Health Organization (WHO) has barred a life sciences industry association from participating in setting global standards protecting food and water supplies because its members have a financial stake in the outcome.
With companies eager to tout their "green" credentials to consumers, advertising watchdogs are stepping up efforts to rein in marketers that make false or exaggerated claims.
In Bayer and the Global Compact, Phillipp Mimkes of the Coalition Against Bayer Dangers looks at Bayer's corporate history and why it may be at odds with the Compact, a partnership between the UN and big business. Here, Mimkes offers a few more reasons.
While 25 million Africans are living with AIDS, Northern pharmaceutical companies and governments are turning their back on the greatest tragedy of our time according to former deputy head of UNICEF.
In the final hectic days before Congress adjourns for the year, lobbyists are swarming around the Capitol, trying to adorn a bill on bioterrorism with all sorts of special-interest provisions.